Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Gregory L. Moore"'
Autor:
Christine Bonzon, Rumana Rashid, Irene Leung, Nicole Rodriguez, Alex Nisthal, Ruschelle Love, Sung-Hyung Lee, Panida Lertkiatmongkol, Sher Karki, Kendra N Avery, Norman J Barlow, Seung Y Chu, Gregory L Moore, John R Desjarlais
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/0bbc3f9cd59949e18f47f70a8c932be8
Autor:
Olivier Nolan-Stevaux, Mercedesz Balazs, Angela Coxon, John R. Desjarlais, Jude Canon, Patricia L. McElroy, Siyuan Liu, Joshua T. Pearson, Ryan Case, Jennitte Stevens, Gregory L. Moore, Umesh S. Muchhal, Matthew J. Bernett, Wendy Zhong, Flordeliza Fajardo, Christina L. Zuch de Zafra
Tables S1 to S6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::892af44b965ae051caf93d900cf95e33
https://doi.org/10.1158/1078-0432.22472553.v1
https://doi.org/10.1158/1078-0432.22472553.v1
Autor:
Olivier Nolan-Stevaux, Mercedesz Balazs, Angela Coxon, John R. Desjarlais, Jude Canon, Patricia L. McElroy, Siyuan Liu, Joshua T. Pearson, Ryan Case, Jennitte Stevens, Gregory L. Moore, Umesh S. Muchhal, Matthew J. Bernett, Wendy Zhong, Flordeliza Fajardo, Christina L. Zuch de Zafra
Affinity measurements and antibody panels
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1230936b22f3f5971b9a0634947ac565
https://doi.org/10.1158/1078-0432.22472556.v1
https://doi.org/10.1158/1078-0432.22472556.v1
Autor:
Olivier Nolan-Stevaux, Mercedesz Balazs, Angela Coxon, John R. Desjarlais, Jude Canon, Patricia L. McElroy, Siyuan Liu, Joshua T. Pearson, Ryan Case, Jennitte Stevens, Gregory L. Moore, Umesh S. Muchhal, Matthew J. Bernett, Wendy Zhong, Flordeliza Fajardo, Christina L. Zuch de Zafra
Purpose:Despite advances in the treatment of multiple myeloma, new therapies are needed to induce more profound clinical responses. T-cell–redirected lysis triggered by bispecific antibodies recruiting T cells to cancer cells is a clinically valida
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::060deecb9202e7b9f4001d1fa15364f6
https://doi.org/10.1158/1078-0432.c.6528261
https://doi.org/10.1158/1078-0432.c.6528261
Autor:
Matthew A. Dragovich, Viralkumar Davra, Matthew S. Faber, Yoon Kyung Kim, Alex Nisthal, Veronica G. Zeng, Jonathan Jacinto, Juan E. Diaz, Thuy Truong, Jing Qi, Kendra N. Avery, Rumana Rashid, Sung-Hyung Lee, Seung Y. Chu, Christine Bonzon, Ruschelle Love, Matthew J. Bernett, James A. Ernst, Rena Bahjat, Norman J. Barlow, John R. Desjarlais, Michael Hedvat, Gregory L. Moore
Publikováno v:
Cancer Research. 83:2983-2983
T cells in the tumor micro-environment require TCR/MHC engagement and co-stimulatory receptor engagement to achieve optimal activation. Solid tumor cells lack expression of CD28 ligands, so we hypothesized that activation of CD28 signaling at the T c
Autor:
Juan Diaz, Rumana Rashid, Umesh Muchhal, Ruschelle Love, Jing Qi, Veronica Zeng, Gregory L. Moore, Christine Bonzon, Norman J. Barlow, Kendra N. Avery, Michael Hedvat, John R. Desjarlais, Irene W. Leung, Matthew Dragovich, Charles G. Bakhit, Michael Hackett
Publikováno v:
Cancer Research. 81:1880-1880
T cells in the tumor micro-environment require TCR/MHC engagement and co-stimulatory receptor engagement to achieve complete activation. Tumor cells lack expression of CD28 ligands, so we hypothesized that activation of CD28 signaling at the T cell/t
Autor:
Umesh Muchhal, Seung Y. Chu, Juan Diaz, Rumana Rashid, John R. Desjarlais, Nargess Hassanzadeh-Kiabi, Katrina Bykova, Alex Nisthal, Kendra N. Avery, Gregory L. Moore
Publikováno v:
Cancer Research. 81:1831-1831
Bispecific T cell engagers simultaneously bind CD3 on T cells and tumor-associated antigens to promote T cell-mediated killing of tumor cells. These agents provide synthetic immunity by expanding, activating, and redirecting T cells against a target
Autor:
Rumana Rashid, Veronica Zeng, Matthew Dragovich, Umesh Muchhal, Michael Hedvat, Erik Weiking Pong, Alex Nisthal, Kendra N. Avery, Gregory L. Moore, Connie Ardila, Seung Y. Chu, John R. Desjarlais, Christine Bonzon
Publikováno v:
Cancer Research. 80:5663-5663
Bispecific antibodies enable therapeutic modalities inaccessible to traditional mAbs, such as T cell engagers that bind both CD3 on T cells and a target antigen on tumor cells. These agents provide synthetic immunity by expanding, activating, and red
Autor:
Rumana Rashid, John R. Desjarlais, Kendra N. Avery, Umesh Muchhal, Matthew S. Faber, Veronica Zeng, John L. Zeytounian, Gregory L. Moore, Michael Hedvat, Matthew J. Bernett
Publikováno v:
Cancer Research. 80:5654-5654
Mesothelin (MSLN) is a tumor-associated antigen highly expressed in ovarian tumors. Current treatment options for ovarian cancer have only modest efficacy and there remains a large unmet need for new targeted therapies. We generated targeted T cell e
Autor:
Nicole Rodriguez, Gregory L. Moore, Connie Ardila, Seung Y. Chu, Sung-Hyung Lee, Alex Nisthal, Umesh Muchhal, Christine Bonzon, Rumana Rashid, Kendra N. Avery, Yoon Kyung Kim, John R. Desjarlais, Liz Bogaert, Irene W. Leung
Publikováno v:
Cancer Research. 80:2286-2286
Bispecific T cell engagers simultaneously bind CD3 on T cells and tumor-associated antigens to promote T cell-mediated killing of tumor cells. While targeting lineage-restricted antigens such as CD19 or CD20 have found clinical success in hematopoiet